References
- Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys 2012; 82: e17-24. doi: 10.1016/j.ijrobp.2010.10.075
- Daşu A. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol 2007; 19: 289-301. doi: 10.1016/j. clon.2007.02.007
- Datta NR, Stutz E, Rogers S, Bodis S. Clinical estimation of α/β values for prostate cancer from isoeffective phase III randomized trials with moderately hypofractionated radiotherapy. Acta Oncol 2018; 57: 883-94. doi: 10.1080/0284186x.2018.1433874
- Liu HX, Du L, Yu W, Cai BN, Xu SP, Xie CB, et al. Hypofractionated helical tomotherapy for older aged patients with prostate cancer: preliminary results of a Phase I-II trial. Technol Cancer Res Treat 2016; 15: 546-54. doi: 10.1177/1533034615593189
- Al-Mamgani A, van Putten WL, Heemsbergen WD, van Leenders GJ, Slot A, Dielwart MF, et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008; 72: 980-8. doi: 10.1016/j.ijrobp.2008.02.073
- Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 2016; 17: 1047-60. doi: 10.1016/s1470-2045(16)30102-4
- Roach M, 3rd, Marquez C, Yuo HS, Narayan P, Coleman L, Nseyo UO, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1994; 28: 33-7. doi: 10.1016/0360-3016(94)90138-4
- Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PWM, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol 2017; 35: 1884-90. doi: 10.1200/ jco.2016.71.7397
- Roach M, 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003; 21: 1904-11. doi: 10.1200/jco.2003.05.004
- Dess RT, Suresh K, Zelefsky MJ, Freedland SJ, Mahal BA, Cooperberg MR, et al. Development and validation of a clinical prognostic stage group system for nonmetastatic prostate cancer using disease-specific mortality results from the International Staging Collaboration for Cancer of the Prostate. JAMA Oncol 2020; 6: 1912-20. doi: 10.1001/jamaoncol.2020.4922
- Fine SW. Evolution in prostate cancer staging: Pathology updates from AJCC 8th edition and opportunities that remain. Adv Anat Pathol 2018; 25: 32732. doi: 10.1097/pap.0000000000000200
- Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341-6. doi: 10.1016/0360-3016(95)00060-c
- Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343-6. doi: 10.1016/0197-2456(96)00075-x
- Edelman S, Liauw SL, Rossi PJ, Cooper S, Jani AB. High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes. Int J Radiat Oncol Biol Phys 2012; 83: 1473-9. doi: 10.1016/j.ijrobp.2011.10.036
- López-Torrecilla J, Pastor-Peidro J, Vicedo-González A, González-Sanchis D, Hernandez-Machancoses A, Almendros-Blanco P, et al. Patterns of treatment failure in patients with prostate cancer treated with 76-80 Gy radiotherapy to the prostate and seminal vesicles ± hormonotherapy. Clin Transl Oncol 2021; 23: 481-90. doi: 10.1007/s12094-020-02437-0
- Pahlajani N, Ruth KJ, Buyyounouski MK, Chen DY, Horwitz EM, Hanks GE, et al. Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer. Int J Radiat Oncol Biol Phys 2012; 82: 1949-56. doi: 10.1016/j.ijrobp.2011.04.005
- Scardino P. Update: NCCN prostate cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 2005; 3 Suppl 1: S29-33. PMID: 16280109
- Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007; 8: 475-87. doi: 10.1016/s1470-2045(07)70143-2
- Michalski JM, Yan Y, Watkins-Bruner D, Bosch WR, Winter K, Galvin JM, et al. Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. Int J Radiat Oncol Biol Phys 2013; 87: 932-8. doi: 10.1016/j.ijrobp.2013.07.041
- Michalski JM, Moughan J, Purdy J, Bosch W, Bruner DW, Bahary JP, et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: The NRG Oncology RTOG 0126 randomized clinical trial. JAMA Oncol 2018; 4: e180039. doi: 10.1001/jamaoncol.2018.0039
- Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol 2016; 34: 2325-32. doi: 10.1200/jco.2016.67.0448
- Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, Yamada Y, et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 2008; 71: 330-7. doi: 10.1016/j. ijrobp.2007.10.004
- Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009; 74: 1405-18. doi: 10.1016/j. ijrobp.2008.10.091
- Viani GA, Viana BS, Martin JE, Rossi BT, Zuliani G, Stefano EJ. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: a randomized clinical trial. Cancer 2016; 122: 2004-11. doi: 10.1002/ cncr.29983
- Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, et al. Hypofractionated radiation therapy for localized prostate cancer: Executive summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline. Pract Radiat Oncol 2018; 8: 354-60. doi: 10.1016/j.prro.2018.08.002
- Arcangeli G, Fowler J, Gomellini S, Arcangeli S, Saracino B, Petrongari MG, et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011; 79: 1013-21. doi: 10.1016/j. ijrobp.2009.12.045
- Arcangeli G, Saracino B, Arcangeli S, Gomellini S, Petrongari MG, Sanguineti G, et al. Moderate hypofractionation in high-risk, organ-confined prostate cancer: Final results of a phase III randomized trial. J Clin Oncol 2017; 35: 1891-7. doi: 10.1200/jco.2016.70.4189
- Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007; 68: 1424-30. doi: 10.1016/j.ijrobp.2007.01.067
- Kupelian PA, Reddy CA, Klein EA, Willoughby TR. Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life. Int J Radiat Oncol Biol Phys 2001; 51: 988-93. doi: 10.1016/s0360-3016(01)01730-8
- Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys 2005; 63: 1463-8. doi: 10.1016/j.ijrobp.2005.05.054
- Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 2013; 31: 3860-8. doi: 10.1200/jco.2013.51.1972
- de Vries KC, Wortel RC, Oomen-de Hoop E, Heemsbergen WD, Pos FJ, Incrocci L. Hyprofractionated versus conventionally fractionated radiation therapy for patients with intermediate- or high-risk, localized, prostate cancer: 7-Year outcomes from the randomized, multicenter, open-label, phase 3 HYPRO trial. Int J Radiat Oncol Biol Phys 2020; 106: 108-15. doi: 10.1016/j. ijrobp.2019.09.007
- Yin Z, You J, Wang Y, Zhao J, Jiang S, Zhang X, et al. Moderate hypofractionated radiotherapy vs conventional fractionated radiotherapy in localized prostate cancer: a systemic review and meta-analysis from Phase III randomized trials. Onco Targets Ther 2019; 12: 1259-68. doi: 10.2147/ott. S181067
- Wen N, Kumarasiri A, Nurushev T, Burmeister J, Xing L, Liu D, et al. An assessment of PTV margin based on actual accumulated dose for prostate cancer radiotherapy. Phys Med Biol 2013; 58: 7733-44. doi: 10.1088/00319155/58/21/7733
- Maund IF, Benson RJ, Fairfoul J, Cook J, Huddart R, Poynter A. Image-guided radiotherapy of the prostate using daily CBCT: the feasibility and likely benefit of implementing a margin reduction. Br J Radiol 2014; 87: 20140459. doi: 10.1259/bjr.20140459
- Utsunomiya S, Yamamoto J, Tanabe S, Oishi M, Satsuma A, Kaidu M, et al. Complementary relation between the improvement of dose delivery technique and PTV margin reduction in dose-escalated radiation therapy for prostate cancer. Pract Radiat Oncol 2019; 9: 172-8. doi: 10.1016/j. prro.2019.02.001
- Murray J, Griffin C, Gulliford S, Syndikus I, Staffurth J, Panades M, et al. A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer. Radiother Oncol 2020; 142: 62-71. doi: 10.1016/j.radonc.2019.10.017
- Meeks SL, Harmon JF, Jr., Langen KM, Willoughby TR, Wagner TH, Kupelian PA. Performance characterization of megavoltage computed tomography imaging on a helical tomotherapy unit. Med Phys 2005; 32: 2673-81. doi: 10.1118/1.1990289
- Murthy V, Krishnatry R, Mallik S, Master Z, Mahantshetty U, Shrivastava S. Helical tomotherapy-based hypofractionated radiotherapy for prostate cancer: a report on the procedure, dosimetry and preliminary clinical outcome. J Cancer Res Ther 2013; 9: 253-60. doi: 10.4103/0973-1482.113378
- Schiller K, Geier M, Duma MN, Nieder C, Molls M, Combs SE, et al. Definitive, intensity modulated tomotherapy with a simultaneous integrated boost for prostate cancer patients - Long term data on toxicity and biochemical control. Rep Pract Oncol Radiother 2019; 24: 315-21. doi: 10.1016/j.rpor.2019.05.004
- Pommier P, Chabaud S, Lagrange JL, Richaud P, Le Prise E, Wagner JP, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study. Int J Radiat Oncol Biol Phys 2016; 96: 759-69. doi: 10.1016/j. ijrobp.2016.06.2455
- Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, et al. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol 2018; 19: 1504-15. doi: 10.1016/ s1470-2045(18)30528-x
- Shiota M, Yokomizo A, Takeuchi A, Imada K, Kiyoshima K, Inokuchi J, et al. The oncological outcome and validation of Japan Cancer of the Prostate Risk Assessment score among men treated with primary androgen-deprivation therapy. J Cancer Res Clin Oncol 2015; 141: 495-503. doi: 10.1007/s00432-014-1828-7
- Kimura K, Tsuzuki T, Kato M, Saito AM, Sassa N, Ishida R, et al. Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens. Prostate 2014; 74: 680-7. doi: 10.1002/pros.22786
- Kato M, Kimura K, Hirakawa A, Kobayashi Y, Ishida R, Kamihira O, et al. Prognostic parameter for high risk prostate cancer patients at initial presentation. Prostate 2018; 78: 11-6. doi: 10.1002/pros.23438
- Feng FY, Huang HC, Spratt DE, Zhao SG, Sandler HM, Simko JP, et al. Validation of a 22-gene genomic classifier in patients with recurrent prostate cancer: An ancillary study of the NRG/RTOG 9601 randomized clinical trial. JAMA Oncol 2021; 7: 544-52. doi: 10.1001/jamaoncol.2020.7671
- Syrigos KN, Karapanagiotou E, Harrington KJ. Prostate cancer in the elderly. Anticancer Res 2005; 25: 4527-33
- Wu YH, Yang WC, Hu YW, Hsieh CM, Yang KL, Lai IC, et al. Definitive radiotherapy for older patients with prostate cancer: Experience of a medical center in Taiwan. Sci Rep 2017; 7: 13880. doi:10.1038/s41598-017-13119-3
- Dell’Oglio P, Boehm K, Trudeau V, Tian Z, Larcher A, Leyh-Bannurah SR, et al. Survival after conservative management versus external beam radiation therapy in elderly patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2016; 96: 1037-45. doi: 10.1016/j.ijrobp.2016.05.004
- Wilson JM, Dearnaley DP, Syndikus I, Khoo V, Birtle A, Bloomfield D, et al. The Efficacy and safety of conventional and hypofractionated high-dose radiation therapy for prostate cancer in an elderly population: A subgroup analysis of the CHHiP trial. Int J Radiat Oncol Biol Phys 2018; 100: 1179-89. doi: 10.1016/j.ijrobp.2018.01.016
- Cuccia F, Fiorentino A, Corrao S, Mortellaro G, Valenti V, Tripoli A, et al. Moderate hypofractionated helical tomotherapy for prostate cancer in a cohort of older patients: a mono-institutional report of toxicity and clinical outcomes. Aging Clin Exp Res 2020; 32: 747-53. doi: 10.1007/s40520-019-01243-1
- Sujenthiran A, Parry M, Nossiter J, Berry B, Cathcart PJ, Clarke NW, et al. Comparison of treatment-related toxicity with hypofractionated or conventionally fractionated radiation therapy for prostate cancer: A National Population-Based Study. Clin Oncol 2020; 32: 501-8. doi: 10.1016/j. clon.2020.02.004